Nifty
Sensex
:
:
10588.65
35955.34
36.95 (0.35%)
111.64 (0.31%)

Pharmaceuticals & Drugs

Rating :
68/99

BSE: 500009 | NSE: AMBASARABH

16.30
02-Jul-2020
  • Open
  • High
  • Low
  • Previous Close
  •  16.10
  •  16.90
  •  16.10
  •  16.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  47
  •  2.43
  •  21.60
  •  9.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 124.91
  • 43.97
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 141.91
  • N/A
  • 4.67

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 30.76%
  • 20.22%
  • 46.99%
  • FII
  • DII
  • Others
  • 0%
  • 0.01%
  • 2.02%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -100.00
  • -100.00
  • -100.00

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -6.68
  • -5.93
  • -15.53

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -15.77
  • -42.65

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 1.21
  • 17.73

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.73
  • 2.44
  • 3.63

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.86
  • 0.94
  • -1.43

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Net Sales
0.00
44.78
-100.00%
31.71
36.74
-13.69%
32.27
34.36
-6.08%
30.95
36.00
-14.03%
Expenses
0.00
42.00
-100.00%
33.40
34.53
-3.27%
32.84
33.67
-2.47%
32.25
35.84
-10.02%
EBITDA
0.00
2.78
-100.00%
-1.69
2.21
-
-0.57
0.69
-
-1.30
0.16
-
EBIDTM
0.00%
6.21%
-5.33%
6.01%
-1.76%
2.00%
-4.21%
0.45%
Other Income
0.00
1.86
-100.00%
3.35
1.28
161.72%
2.23
1.11
100.90%
2.89
1.23
134.96%
Interest
0.00
0.57
-100.00%
0.55
1.18
-53.39%
0.99
0.60
65.00%
0.93
0.89
4.49%
Depreciation
0.00
0.54
-100.00%
0.52
0.53
-1.89%
0.50
0.51
-1.96%
0.51
0.52
-1.92%
PBT
0.00
3.53
-100.00%
0.58
1.78
-67.42%
0.17
0.68
-75.00%
0.15
-0.02
-
Tax
0.00
2.49
-100.00%
-0.07
0.05
-
-0.12
1.12
-
-0.04
0.31
-
PAT
0.00
1.04
-100.00%
0.65
1.73
-62.43%
0.29
-0.44
-
0.19
-0.33
-
PATM
0.00%
2.32%
2.05%
4.70%
0.88%
-1.27%
0.61%
-0.91%
EPS
0.00
0.14
-100.00%
0.08
0.23
-65.22%
0.04
-0.06
-
0.02
-0.04
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
139.71
151.88
125.00
133.88
131.98
124.50
104.65
100.24
88.98
79.51
75.03
Net Sales Growth
-6.57%
21.50%
-6.63%
1.44%
6.01%
18.97%
4.40%
12.65%
11.91%
5.97%
 
Cost Of Goods Sold
84.76
89.52
70.20
76.92
72.88
72.73
58.10
54.18
51.56
50.14
47.50
Gross Profit
54.95
62.36
54.81
56.95
59.11
51.76
46.55
46.07
37.42
29.37
27.53
GP Margin
39.33%
41.06%
43.85%
42.54%
44.79%
41.57%
44.48%
45.96%
42.05%
36.94%
36.69%
Total Expenditure
140.49
145.99
136.74
144.95
144.67
128.83
113.27
110.61
101.33
99.15
95.91
Power & Fuel Cost
-
3.22
2.84
2.68
3.67
2.80
2.36
2.97
2.11
2.23
2.21
% Of Sales
-
2.12%
2.27%
2.00%
2.78%
2.25%
2.26%
2.96%
2.37%
2.80%
2.95%
Employee Cost
-
24.57
26.67
28.71
31.29
28.47
27.39
30.28
26.86
25.66
26.75
% Of Sales
-
16.18%
21.34%
21.44%
23.71%
22.87%
26.17%
30.21%
30.19%
32.27%
35.65%
Manufacturing Exp.
-
5.08
5.18
5.43
7.13
5.53
6.00
5.12
4.53
3.84
3.05
% Of Sales
-
3.34%
4.14%
4.06%
5.40%
4.44%
5.73%
5.11%
5.09%
4.83%
4.07%
General & Admin Exp.
-
12.23
24.21
12.52
13.39
10.03
9.56
8.93
7.09
5.21
5.96
% Of Sales
-
8.05%
19.37%
9.35%
10.15%
8.06%
9.14%
8.91%
7.97%
6.55%
7.94%
Selling & Distn. Exp.
-
8.06
4.86
6.53
6.42
6.08
4.66
4.11
4.12
5.18
2.57
% Of Sales
-
5.31%
3.89%
4.88%
4.86%
4.88%
4.45%
4.10%
4.63%
6.51%
3.43%
Miscellaneous Exp.
-
3.32
2.79
12.16
9.90
3.19
5.18
5.02
5.05
6.88
2.57
% Of Sales
-
2.19%
2.23%
9.08%
7.50%
2.56%
4.95%
5.01%
5.68%
8.65%
12.49%
EBITDA
-0.78
5.89
-11.74
-11.07
-12.69
-4.33
-8.62
-10.37
-12.35
-19.64
-20.88
EBITDA Margin
-0.56%
3.88%
-9.39%
-8.27%
-9.62%
-3.48%
-8.24%
-10.35%
-13.88%
-24.70%
-27.83%
Other Income
10.33
5.47
25.04
6.22
95.08
12.99
3.01
16.41
4.08
8.74
3.97
Interest
3.04
3.29
3.41
4.77
4.10
9.83
10.93
8.52
9.69
11.30
1.95
Depreciation
2.07
2.10
2.12
4.27
16.54
4.81
3.01
14.02
2.90
2.78
2.68
PBT
4.43
5.97
7.77
-13.90
61.74
-5.98
-19.55
-16.50
-20.86
-24.98
-21.55
Tax
2.26
3.97
6.69
4.61
13.61
0.69
0.66
1.48
1.04
3.87
5.05
Tax Rate
51.02%
66.50%
86.10%
-33.17%
22.04%
-11.54%
-3.38%
-8.97%
-10.75%
-52.58%
105.21%
PAT
2.17
2.00
1.08
-18.51
48.14
-6.67
-20.21
-17.97
-10.71
-11.23
-0.26
PAT before Minority Interest
2.18
2.00
1.08
-18.51
48.14
-6.67
-20.21
-17.97
-10.71
-11.23
-0.26
Minority Interest
0.01
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
1.55%
1.32%
0.86%
-13.83%
36.48%
-5.36%
-19.31%
-17.93%
-12.04%
-14.12%
-0.35%
PAT Growth
-54.32%
85.19%
-
-
-
-
-
-
-
-
 
EPS
0.28
0.26
0.14
-2.42
6.28
-0.87
-2.64
-2.35
-1.40
-1.47
-0.03

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
30.62
26.52
25.17
38.73
-9.40
-2.16
17.94
36.46
47.38
58.92
Share Capital
76.63
76.63
76.63
76.63
76.63
76.63
76.63
76.63
76.63
76.63
Total Reserves
-46.01
-50.12
-51.46
-37.90
-86.04
-78.79
-58.69
-40.18
-29.25
-17.71
Non-Current Liabilities
8.90
11.39
5.83
12.70
15.43
59.01
17.14
15.99
21.37
14.30
Secured Loans
8.76
11.12
5.11
5.72
5.76
3.20
4.09
3.25
12.62
8.68
Unsecured Loans
0.00
0.00
0.00
0.02
0.00
0.00
0.00
0.00
8.56
5.50
Long Term Provisions
3.80
4.38
5.53
6.75
9.85
55.84
12.33
12.30
0.00
0.00
Current Liabilities
171.32
155.44
124.43
152.51
162.77
154.55
175.34
170.71
171.90
148.03
Trade Payables
46.83
39.76
29.14
26.93
27.54
28.33
21.13
33.31
31.70
31.59
Other Current Liabilities
91.29
80.43
50.08
56.70
91.85
86.32
73.61
65.73
71.01
50.79
Short Term Borrowings
28.76
30.34
35.33
39.50
38.92
36.67
33.45
24.55
0.00
0.00
Short Term Provisions
4.44
4.91
9.88
29.38
4.46
3.22
47.15
47.12
69.19
65.64
Total Liabilities
210.83
193.35
155.43
203.94
168.80
211.40
210.42
223.16
240.65
221.25
Net Block
57.65
59.16
72.25
71.76
90.78
94.32
98.39
111.21
112.22
108.55
Gross Block
65.91
65.36
76.34
138.02
153.64
152.39
154.51
155.91
153.82
155.00
Accumulated Depreciation
8.26
6.20
4.09
66.26
62.86
58.07
56.11
44.69
41.60
46.45
Non Current Assets
94.58
79.79
82.18
91.54
100.43
143.97
105.56
122.72
115.57
115.35
Capital Work in Progress
24.06
13.69
3.44
8.97
0.83
0.21
0.10
0.12
1.12
4.36
Non Current Investment
9.36
5.37
4.83
8.10
0.62
0.78
1.30
2.29
2.23
2.44
Long Term Loans & Adv.
1.98
1.48
1.50
1.95
7.73
48.44
2.79
2.61
0.00
0.00
Other Non Current Assets
1.53
0.10
0.17
0.77
0.48
0.22
2.98
6.48
0.00
0.00
Current Assets
116.26
113.55
73.25
112.40
68.37
67.43
104.85
100.43
125.08
105.90
Current Investments
0.00
0.00
0.00
0.00
0.27
0.15
0.00
0.00
0.00
0.00
Inventories
14.98
14.39
13.81
14.41
17.10
15.13
13.72
12.19
10.15
9.53
Sundry Debtors
34.69
34.13
28.95
30.11
25.29
27.18
27.84
21.91
31.61
22.89
Cash & Bank
23.26
22.07
16.71
16.41
13.85
12.28
7.16
9.46
17.50
16.81
Other Current Assets
43.33
25.29
2.39
13.49
11.86
12.68
56.14
56.87
65.82
56.67
Short Term Loans & Adv.
27.39
17.66
11.38
37.98
11.41
11.18
54.83
55.48
65.82
56.67
Net Current Assets
-55.06
-41.89
-51.18
-40.11
-94.40
-87.12
-70.48
-70.28
-46.82
-42.13
Total Assets
210.84
193.34
155.43
203.94
168.80
211.40
210.41
223.15
240.65
221.25

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
18.80
-7.39
5.40
-74.99
-8.32
11.02
-3.26
-12.80
-3.29
-23.20
PBT
8.21
7.96
-13.62
61.74
-5.98
-19.55
-16.50
-9.67
-11.23
-0.26
Adjustment
1.79
-11.90
17.83
-67.13
2.50
14.47
6.76
-1.90
0.57
-15.02
Changes in Working Capital
16.64
16.46
2.77
-64.49
-0.39
17.76
8.26
8.98
10.53
-8.36
Cash after chg. in Working capital
26.65
12.53
6.98
-69.88
-3.88
12.67
-1.48
-2.60
-0.13
-23.64
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-7.84
-19.93
-1.58
-5.12
-4.44
-1.66
-1.78
-10.21
-3.15
0.44
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-9.25
17.58
-3.31
80.06
9.80
-0.89
-0.28
10.79
8.25
19.89
Net Fixed Assets
-0.06
1.03
56.92
20.63
0.40
0.84
2.06
0.91
9.21
0.88
Net Investments
-0.09
8.92
6.72
-26.62
-0.13
1.83
0.50
-1.55
-12.78
-3.06
Others
-9.10
7.63
-66.95
86.05
9.53
-3.56
-2.84
11.43
11.82
22.07
Cash from Financing Activity
-6.07
-2.09
-6.26
-3.44
-0.61
-8.39
2.75
0.65
-4.27
3.33
Net Cash Inflow / Outflow
3.49
8.10
-4.17
1.62
0.87
1.74
-0.79
-1.36
0.69
0.02
Opening Cash & Equivalents
13.51
5.41
9.58
8.40
7.53
5.79
6.58
7.93
16.81
16.80
Closing Cash & Equivalent
17.00
13.51
5.41
10.03
8.40
7.53
5.79
6.58
17.50
16.81

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
4.00
3.46
3.28
5.05
-1.23
-0.28
2.34
4.76
6.18
7.69
ROA
0.99%
0.62%
-10.30%
25.83%
-3.51%
-9.58%
-8.29%
-4.62%
-4.86%
-0.11%
ROE
7.01%
4.20%
-57.92%
328.25%
0.00%
-256.13%
-66.09%
-25.55%
-21.12%
-0.45%
ROCE
13.17%
16.34%
-11.94%
107.14%
10.08%
-17.91%
-12.98%
0.02%
5.56%
9.79%
Fixed Asset Turnover
2.31
1.77
1.27
0.93
0.83
0.70
0.66
0.59
0.53
0.53
Receivable days
82.69
91.65
79.06
74.77
75.18
93.62
88.35
106.91
121.91
122.70
Inventory Days
35.30
40.98
37.78
42.53
46.19
49.09
46.00
44.61
44.01
45.43
Payable days
117.69
109.36
81.80
71.83
85.02
86.62
87.50
128.12
130.71
302.86
Cash Conversion Cycle
0.30
23.27
35.04
45.47
36.35
56.09
46.86
23.40
35.22
-134.73
Total Debt/Equity
1.31
1.63
1.67
1.22
-4.94
-19.21
2.17
0.81
0.45
0.24
Interest Cover
2.81
3.28
-1.91
16.06
0.39
-0.79
-0.94
0.00
0.35
3.46

News Update:


  • CDSO grants manufacturing license to Ambalal Sarabhai’s arm’s JV for Covid-19 RT-PCR test kits
    28th Apr 2020, 09:49 AM

    CoSara Diagnostics has been granted manufacturing license by Central Drugs Standard Control Organization, Delhi

    Read More
  • Ambalal Sarabhai Enterprises’ arm’s JV starts import of test kits of Covid-19
    17th Apr 2020, 09:22 AM

    CoSara will be marketing pan India the US FDA and CE approved kits of its joint venture partner CoDiagnostics Inc, USA

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.